Compare Heron Therapeutics Inc (HRTX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while YieldMax Universe Fund of Option Income ETFs trades at $7.56 (market cap $369.61M). The key difference: YieldMax Universe Fund of Option Income ETFs is far larger — about 5× Heron Therapeutics Inc's market cap, and YieldMax Universe Fund of Option Income ETFs is more actively traded (659,132 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| HRTX | YMAX | |
|---|---|---|
Market Cap | $74.04M | $369.61M |
Volume | 3,668,095 | 659,132 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $12.98 |
52-Week Low | $0.27 | $7.27 |
Typical Hold Time | 35 Days | 55 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a high distribution yield with weekly dividends, though recent coverage highlights concerns about NAV erosion and sustainability. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure, while support levels cluster around $7-8.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV performance. While the high yield attracts income investors, the fund faces risks from its fee structure and portfolio strategy. Analyst sentiment appears mixed with some highlighting yield benefits while others warn of principal erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
